Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
START CARE childhood asthma trial
ACTRN12622001217796Phase 3Completed
- Sponsor
- Medical Research Institute of New Zealand
- Start
- Dec 2022
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of budesonide + formoterol, budesonide and terbutaline in asthma (2 arms), sponsored by Medical Research Institute of New Zealand. Primary endpoint: Asthma exacerbations rate. Started Dec 2022; status: completed.
02
Drugs
budesonide + formoterolbudesonideterbutaline
03
Conditions
asthma
Beyond the preview
Go deeper on ACTRN12622001217796.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12622001217796.